

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**Equality and health inequality impact assessment**

**Serplulimab with carboplatin and etoposide for  
untreated extensive-stage small-cell lung cancer**

**[ID6346]**

**Final draft guidance (when issued)**

- 1 Have any additional potential equality or health inequality issues been raised during consultation on the draft guidance? If so, how has the committee addressed these?**

No equality issues identified

- 2 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

No equality issues identified

- 3 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

No equality issues identified

- 4 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments in the recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove**

**or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE’s obligations to promote equality.**

No equality issues identified

**5 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?**

No health inequality issues identified

**6 Have the committee’s considerations of equality and health inequality issues been described in the final draft guidance? If so, where?**

Section 3.17 of the final draft guidance

**Approved by senior responsible officer:** Ross Dent

**Date:** 05/05/2026